ZimVie (NASDAQ:ZIMV) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of ZimVie (NASDAQ:ZIMV) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $20.00 price objective on the stock.

Separately, Barclays upped their price objective on shares of ZimVie from $13.00 to $16.00 and gave the company an underweight rating in a report on Tuesday, March 5th.

ZimVie Price Performance

Shares of NASDAQ ZIMV opened at $18.25 on Tuesday. The firm has a 50-day simple moving average of $16.32 and a 200-day simple moving average of $16.98. The stock has a market capitalization of $498.02 million, a price-to-earnings ratio of -1.31 and a beta of 2.16. The company has a quick ratio of 2.23, a current ratio of 2.68 and a debt-to-equity ratio of 1.32. ZimVie has a 52 week low of $6.52 and a 52 week high of $20.91.

ZimVie (NASDAQ:ZIMV) last issued its earnings results on Wednesday, May 8th. The company reported $0.08 EPS for the quarter. ZimVie had a negative net margin of 56.31% and a positive return on equity of 2.01%. The business had revenue of $118.20 million during the quarter. During the same quarter last year, the company earned $0.25 earnings per share. On average, equities analysts predict that ZimVie will post 0.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ZimVie

Hedge funds have recently modified their holdings of the company. Scarborough Advisors LLC purchased a new position in ZimVie during the fourth quarter worth about $28,000. Heritage Wealth Advisors boosted its stake in ZimVie by 172,750.0% during the first quarter. Heritage Wealth Advisors now owns 6,914 shares of the company’s stock worth $114,000 after buying an additional 6,910 shares during the period. EMC Capital Management purchased a new position in ZimVie during the first quarter worth about $228,000. SG Americas Securities LLC lifted its position in shares of ZimVie by 27.2% during the fourth quarter. SG Americas Securities LLC now owns 14,152 shares of the company’s stock worth $251,000 after purchasing an additional 3,029 shares in the last quarter. Finally, Bailard Inc. acquired a new stake in shares of ZimVie during the fourth quarter worth about $254,000. Hedge funds and other institutional investors own 95.63% of the company’s stock.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.